Zsa Zsa Weerts

Chapter 10 248 References 1. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653-654. 2. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-1491. 3. Lea R, Hopkins V, Hastleton J, et al. Diagnostic criteria for irritable bowel syndrome: utility and applicability in clinical practice. Digestion 2004;70:210-213. 4. Mujagic Z, Jonkers D, Hungin APS, et al. Use of Rome criteria for the diagnosis of irritable bowel syndrome in primary care: a survey among European countries. Eur J Gastroenterol Hepatol 2017;29:651-656. 5. Camilleri M. Do the Symptom-Based, Rome Criteria of Irritable Bowel Syndrome Lead to Better Diagnosis and Treatment Outcomes? The Con Argument. Clin Gastroenterol Hepatol 2009;8:129. 6. Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol 2016:1:133- 146. 7. Chang L, Di Lorenzo C, Farrugia G, et al. Functional Bowel Disorders: A Roadmap to Guide the Next Generation of Research. Gastroenterology 2018;154:723-735. 8. Aziz I, Tornblom H, Palsson OS, et al. How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. Am J Gastroenterol 2018;DOI 10.1038/s41395- 018-0074-z. 9. Van den Houte K, Carbone F, Pannemans J, et al. Prevalence and impact of self-reported irritable bowel symptoms in the general population. United Eur Gastroenterol J 2018;7:307-315. 10. Jossan N, Simren M, Sperber A, et al. Health Care Utilization for Rome IV Irritable Bowel Syndrome; A Three-Country Survey in the General Population. Gastroenterology 2017;152:S68. 11. Hungin AP, Whorwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003;17:643-650. 12. Spiegel BM, Farid M, Esrailian E, et al. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010;105:848-858. 13. Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999;94:2912-2917. 14. Corsetti M, Whorwell P. The global impact of IBS: time to think about IBS-specific models of care? Therap Adv Gastroenterol 2017;10:727- 736. 15. Simren M, Tornblom H, Palsson OS, et al. Management of the multiple symptoms of irritable bowel syndrome. Lancet Gastroenterol Hepatol 2017:2:112-122. 16. Rao S, Lembo A, Shiff S, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107:1714-1724. 17. Brenner D, Fogel R, Dorn S, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol 2018;113:735-745. 18. Khanna R, MacDonald J, Levesque B. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 2014;48:505-512. 19. Ballou S, Beath A, Kaptchuk TJ, et al. Factors Associated With Response to Placebo in Patients With Irritable Bowel Syndrome and Constipation. Clin Gastroenterol Hepatol 2018;16:1738-1744 e1731. 20. Shah E, Pimentel M. Placebo effect in clinical trial design for irritable bowel syndrome. J Neurogastroenterol Motil 2014;20:163-170. 21. Lacy B, Lembo A, Macdougall J, et al. Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C. Neurogastroenterol Motil 2014;26:326-333. 22. Black CJ, Moayyedi P, Quigley EMM, et al. Peppermint Oil in Irritable Bowel Syndrome. Gastroenterology 2020;159:395-396.